

Medical Policy: Chemical Peels (Commercial)



POLICY NUMBER	EFFECTIVE DATE	APPROVED BY
MG.MM.ME.54C4	01/01/2020	MPC (Medical Policy Committee)

IMPORTANT NOTE ABOUT THIS MEDICAL POLICY:

Property of ConnectiCare, Inc. All rights reserved. The treating physician or primary care provider must submit to ConnectiCare, Inc. the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, ConnectiCare will not be able to properly review the request for prior authorization. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. The clinical review criteria expressed below reflects how ConnectiCare determines whether certain services or supplies are medically necessary. ConnectiCare established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). ConnectiCare, Inc. expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. Each benefit plan defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by ConnectiCare, as some plans exclude coverage for services or supplies that ConnectiCare considers medically necessary. If there is a discrepancy between this guideline and a member's benefits plan, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of the State of CT and/or the Federal Government. Coverage may also differ for our Medicare members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including including National Coverage Determinations (NCD), Local Coverage Determinations (LCD) and/or Local Medical Review Policies(LMRP). All coding and web site links are accurate at time of publication.

Definitions

Actinic keratosis (AK)	Actinic keratoses (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. Although most AKs do not progress to squamous cell carcinoma (SCC), AKs are a concern because the majority of cutaneous SCCs arise from pre-existing AKs, and AKs that will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist.
------------------------	--

Chemical peel	Controlled removal of varying layers of the skin with use of caustic chemical agents; resulting in a thinner, more compact stratum corneum, thicker epidermis, and uniform distribution of melanin. Peels are typically categorized according to dept and agent used	
	Depth	Agents
	Very superficial (see Limitations/Exclusions)	Glycolic acid, 30-50 percent applied for 1-2 minutes
		Jessner (resorcinol, salicylic acid, lactic acid, ethanol) solution applied in 1-3 coats
		Low concentration resorcinol, 20-30 percent applied for 5-10 minutes
		TCA (trichloroacetic acid) 10 percent applied in 1 coat
	Superficial (See Limitations/Exclusions)	Glycolic acid, 50-70 percent, applied for 2-5 minutes
		Pyruvic acid, 40-50 percent applied for 3-5 minutes
		Jessner solution applied in 4-10 coats
		Resorcinol, 40-50 percent applied for 30-60 minutes
		TCA, 10-30 percent
	Medium	Glycolic acid 70 percent applied for 3-15 minutes
		Pyruvic acid 60 percent applied for 3-5 minutes
		TCA, 35-50 percent
		Augmented TCA (carbon dioxide and TCA 35 percent; Jessner solution and TCA 35 percent; glycolic acid 70 percent and TCA 35 percent)
Deep	Phenol 88 percent	
	Baker-Gordon phenol formula (88 percent phenol, distilled water, septisol, croton oil)	
Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what's new and what isn't new but still works well. Facial Plast Surg 2009; 25:329.		

Coding Criteria

To access the codes, please download the policy **to your computer, and click on the paperclip icon within the policy**

	Applicable CPT and Diagnosis Codes
--	---

Guideline

Medium or deep chemical peels are considered medically necessary for > 10 actinic keratoses (or other premalignant skin lesions) due to the impracticality of treating large numbers of lesions individually.

Limitation/Exclusion

1. Chemical peels are not considered medically necessary for the treatment of active acne vulgaris due to insufficient evidence of therapeutic value.
2. Chemical peels are not considered medically necessary when for the following cosmetic purposes (list not all-inclusive):
 - a. Acne scarring (case-by-case review when documentation substantiating medical necessity is submitted to the plan)
 - b. Contouring/discoloration/hyperpigmentation (e.g., dermatosis papulosa nigra, rosacea)
 - c. Dull complexity
 - d. Ephelides (freckles)
 - e. Fine/fewer lines and wrinkles
 - f. Lentigines (liver spots; aka age spots)
 - g. Melasma
 - h. Photoaged skin
 - i. Sebaceous hyperplasia (aka senile hyperplasia)
 - j. Seborrheic keratoses
 - k. Skin roughness

References

Cleveland Clinic. Common Benign Growths. June 2017.

<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/dermatology/common-benign-growths/Default.htm>. Accessed August 17, 2018.

Branham GH, Thomas JR. Rejuvenation of the skin surface: Chemical peel and dermabrasion. *Facial Plast Surg*. 1996;12(2):125-133.

Brodland DG, Roenigk RK. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. *Mayo Clin Proceed*. 1988;63(9):887-896.

Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. *Cancer* 2009; 115:2523.

Demas PN, Bridenstine JB, Braun TW. Pharmacology of agents used in the management of patients having skin resurfacing. *J Oral Maxillofac Surg*. 1997;55(11):1255-1258.

de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. *Br J Dermatol* 2007; 156(2):222-30.

Dreno B, Fischer TC, Perosino E, et al. Expert opinion: Efficacy of superficial chemical peels in active acne management --what can we learn from the literature today? Evidence-based recommendations. *J Eur Acad Dermatol Venereol*. 2011;25(6):695-704.

Fulton JE Jr. Dermabrasion, chemabrasion, and laserabrasion. Historical perspectives, modern dermabrasion techniques, and future trends. *Dermatol Surg*. 1996;22(7):619-628.

Giese SY, McKinney P, Roth SI, Zukowski M. The effect of chemosurgical peels and dermabrasion on dermal elastic tissue. *Plast Reconstr Surg*. 1997;100(2):489-500.

Fabbrocini G, De Padova MP, Tosti A. Chemical peels: what's new and what isn't new but still works well. *Facial Plast Surg* 2009; 25:329.

Godin DA, Graham HD 3rd. Chemical peels. *J La State Med Soc.* 1998;150(11):513-520.
Gupta AK, Inniss K, Wainwright R, et al. Interventions for actinic keratoses (Protocol for Cochrane Review). *Cochrane Database Syst Rev.* 2003;(4):CD004415.

Gutling M. Chemical peel--current possibilities and limits. *Ther Umsch.* 1999;56(4):182-187.
Handog EB, Datuin MS, Singzon IA. Chemical peels for acne and acne scars in Asians: Evidence based review. *J Cutan Aesthet Surg.* 20125(4):239-246.

Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. *J Am Acad Dermatol.* 1996;34(4):638-644.

Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. *Am Fam Physician.* 2000;62(2):357-368, 375-376, 381-382.

Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. *Dermatol Surg.* 2004;30(5):756-760; discussion 760.

Khunger N; IADVL Task Force. Standard guidelines of care for chemical peels. *Indian J Dermatol Venereol Leprol.* 2008;74 Suppl:S5-S12.

Lee SH, Huh CH, Park KC, Youn SW. Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients. *J Eur Acad Dermatol Venereol.* 2006;20(8):964-968.

Monheit GD. Medium-depth chemical peels. *Dermatol Clin.* 2001;19(3):413-425, vii.

Montemarano AD. Melasma. *eMedicine Dermatology Topic 260.* Omaha, NE: eMedicine.com; updated June 25, 2003.

Morganroth GS, Leffell DJ. Nonexcisional treatment of benign and premalignant cutaneous lesions. *Clin Plast Surg.* 1993;20:91-104.

National Comprehensive Cancer Network. NCCN Guidelines Squamous Cell Skin Cancer. Version 2.2019. http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed August 17, 2018.

Perras C. Imiquimod 5% cream for actinic keratosis. *Issues in Emerging Health Technologies.* Issue 61. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2004.

Roenigk RK, Brodland DG. A primer of facial chemical peel. *Dermatol Clin.* 1993;11(2):349-359.

Rubin MG. A peeler's thoughts on skin improvement with chemical peels and laser resurfacing. *Clin Plast Surg.* 1997;24(2):407-409.

Samuel M, Brooke RCC, Hollis S, Griffiths CEM. Interventions for photodamaged skin. *Cochrane Database Syst Rev.* 2005;(1):CD001782.

Simonart T. Newer approaches to the treatment of acne vulgaris. *Am J Clin Dermatol.* 2012;13(6):357-364.

Medical Policy: Chemical Peels (Commercial)



Specialty matched clinical peer review.

Steinsapir KD. The chemical peel. *Int Ophthalmol Clin.* 1997;37(3):81-96.

Strauss JS, Krowchuk DP, Leyden JJ, et al. American Academy of Dermatology. Guidelines of care for acne vulgaris management. *J Am Acad Dermatol.* 2007;56-651-653.

Tse Y, Ostad A, Lee HS, et al. A clinical and histologic evaluation of two medium-depth peels. Glycolic acid versus Jessner's trichloroacetic acid. *Dermatol Surg.* 1996;22(9):781-786.

Van Scott EJ, Yu RJ. Alpha hydroxy acids: Procedures for use in clinical practice. *Cutis.* 1989;43:222-228.

Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. *Dermatol Surg.* 1997;23(3):191-196.

Revision history

DATE	REVISION
01/01/2020	New policy. Connecticare has adopted the clinical criteria of its parent corporation, Emblem Health.